About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

In Neurocritical Care Patients, Intermediate Glucose Control may be Better Than Tight One

by Kathy Jones on October 23, 2012 at 8:48 PM
Font : A-A+

 In Neurocritical Care Patients, Intermediate Glucose Control may be Better Than Tight One

Intensive glycemic control does not reduce mortality in neurocritical care patients and could lead to more neurological damage, says a new study in BioMed Central's open access journal Critical Care.

Complicating the picture, poor glucose control also leads to worse recovery and should be avoided. This study suggests that a strategy to maintain intermediate glucose levels would contribute to better outcomes in these patients.

Advertisement

Hyperglycemia and hypoglycemia are common in critically ill patients and are strongly associated with worse outcomes. This is particularly important for neurologically ill patients, for whom poor glycemic control could contribute to secondary neurological damage. Hyperglycemia is known to be very harmful in such patients, potentially leading to further brain damage andincreased mortality.

On the other hand, hypoglycemia could cause neuroglycopenia - a shortage of glucose in the brain - which can lead to loss of consciousness, brain damage and, in some cases, even death. For these reasons, the same optimal glycemic targets for general critical care patients may not apply for neurologically injured patients.
Advertisement

Numerous randomized controlled trials (RCTs) have assessed the efficacy and safety of intensive insulin therapy and tight glycemic control regimens for critically ill patients, though these largely focus on mortality as the primary outcome, rather than functional recovery, which would be a more meaningful endpoint for neurological patients.

With the aim of determining better glycemic targets for neurologically injured patients, a research group from the Department of Critical Care Medicine at the University of Calgary, Canada, performed a systematic review and meta-analysis of RCTs comparing intensive insulin therapy to conventional glycemic control, among patients with neurological injuries, including traumatic brain injury, ischemic or hemorrhagic stroke, anoxic encephalopathy, central nervous system infection or spinal cord injury.

Sixteen RCTs, a combined total of 1,248 neurocritical care patients, were included. In the trials, glycemic control targets with intensive insulin ranged from 70-140 mg/dl, while conventional protocols aimed to keep glucose levels below 144-300 mg/dl.

Consistent with the results of recent large multicenter RCTs in non-neurological patients, the authors found that intensive glucose control did not reduce mortality among their neurocritical care patients, but it did reduce the occurrence of poor neurological outcomes. However, intensive insulin therapy significantly increases the risk of hypoglycemia. A benefit was not observed when intensive treatment was compared with more intermediate glycemic targets of 110-180mg/dl.

According to lead author Andreas Kramer, "Tight glucose control doesn't appear to improve mortality in neurocritical care patients." He continued, "Very loose glucose control is associated with worse neurological recovery and should be avoided. Our results support targeting more intermediate glycemic goals."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Lung Transplantation
Baldness can be Cured and Prevented: let us see How!
Drinking Beer or Wine Every Day Could Cause Age-related Diseases
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Diabetes - Foot Care Sugar: Time to Look beyond Its Sweetness Diabetic Ketoacidosis 

Most Popular on Medindia

Blood Pressure Calculator Blood Donation - Recipients Turmeric Powder - Health Benefits, Uses & Side Effects Sanatogen Noscaphene (Noscapine) Color Blindness Calculator Vent Forte (Theophylline) Loram (2 mg) (Lorazepam) A-Z Drug Brands in India Daily Calorie Requirements
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use